FDA Inspection
Novartis Pharma AGNovartis Pharma AG – FDA Inspection, Aug 29, 2019
Record Details
This FDA Inspection record concerns Novartis Pharma AG, with an inspection on August 29, 2019, issued by the Office of Inspections and Investigations, covering human drugs.
- Person
- Maxwell L. Van Tassell (Issuing Officer)
View Company Profile
ID · 0857ce8e-6530-4997-b440-9f2dae82399a
Inspection Facts
- Inspection number
- 1109986
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Novartis Pharma AG
10| Date | Classification | Office | Project area |
|---|---|---|---|
| August 30, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 12, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 20, 2018 | Not classified | Office of Inspections and Investigations | |
| July 6, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 14, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Novartis Pharma AG
- FDA Inspection 1180833 - 2022-08-30
- FDA Inspection 1099919 - 2019-07-12
- FDA Inspection 1053787 - 2018-04-20
- FDA Inspection 1021086 - 2017-07-06
- FDA Inspection 916149 - 2015-01-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.